
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc. is strategically positioned for long-term revenue growth through its co-commercialization options in key programs and a robust pipeline that includes innovative gene therapy solutions targeting severe neurological diseases. The company's TRACER platform has the potential to provide significant value for shareholders, supported by recent clinical advancements and a strong safety profile, which has seen no serious adverse events reported. Additionally, an extended cash runway into mid-2027 allows Voyager to focus on its Alzheimer’s programs, further enhancing its capacity to develop effective therapies that may outperform existing treatments in the market.
Bears say
Voyager Therapeutics is facing significant financial risks, evidenced by a reported net loss of ($1.13) per share and a lack of generated sales revenue, which delays the company's path to profitability. The potential for negative study results or adverse regulatory decisions poses an additional threat to the company's revenue projections and valuation estimates, particularly for its key programs like VY7523 and VY9323. Furthermore, intense competition in the therapeutic development space, with multiple tau antibody programs advancing ahead of VY7523, raises concerns about the company's ability to capture market share even if regulatory approvals are obtained.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares